Bruker Clocks 19% Jump In Q3 Sales; Lifts FY21 Guidance

  • Bruker Corp's BRKR Q3 revenues were $608.9 million, up 19.1 Y/Y (17.8% organically) and beating the Wall Street estimate of $574.17 million.
  • The company saw a 1% positive effect on revenues from currency translation and a positive impact of less than 1% from acquisitions.
  • Adjusted EPS increased from $0.42 to $0.63, surpassing the consensus of $0.44.
  • The company's CALID group, which houses its life sciences and mass spectrometry business, posted 13% growth with revenues of $194.2 million.
  • Revenues for Bruker BioSpin increased 22% to $186.5 million, Bruker Nano sales rose 19% to $174.9 million, and Bruker Energy & Supercon Technologies revenues rose 30% to $57.0 million.
  • On an adjusted basis, gross margin expanded 210 basis points to 51.7%, and operating margin increased 200 basis points to 20.6%.
  • FY21 Guidance: Bruker raised FY21 guidance significantly on solid demand for its products and solutions.
  • The company projects revenue growth of 19.5% - 20.5% and organic revenue growth of 16.5% - 17.5% up from its previous projection of 17%-19% and 14%-16%, respectively.
  • It expects adjusted EPS of $2.05 - $2.09 (consensus of $1.93), up from its previous guidance of $1.88-$1.93.
  • Price Action: BRKR shares closed higher by 1.15% at $81.22 on Monday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: EarningsNewsGuidanceHealth CareGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!